FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
Season 9, Episode 3, Jun 15, 2023, 06:10 PM
Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.